Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

The drug candidate is a single polypeptide comprising a single-chain variable fragment (scFv) targeting cancer surface antigen DLL3 and two single-domain antibodies that binds to the CD3 epsilon ...

A breakthrough in Russia promises to redefine cancer treatment, with the country announcing its first mRNA cancer vaccine.

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Immune checkpoint inhibitors, drugs that can help make the immune system recognize and destroy cancer more aggressively, are one of the most important medicines in cancer treatment today.

The global market for oncology drugs was valued at US$231.56 billion last year and is projected to soar to US$532.91 billion by 2031, according to Coherent (NYSE: COHR) Market Insights.

Without our immune system, we wouldn't last very long: this complex network of organs and cells fights off pathogens and ...

A novel geometric deep learning framework designs ligand-specific protein binders, enhancing therapeutic potential in cell ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between 5 and 12 months after ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...